Pfizer thinks it can add $25 billion of risk-adjusted revenues to its 2030 top line through dealmaking, CEO Albert Bourla told investors during a conference call in February. The company's business development efforts will target both late-stage assets and early innovation, he said. The focus will be on therapeutic areas and platforms it can add value to.